American Pharmacy News Reports Stories

The study is to be completed prior to the submission of a Biologicals Licensing Application.

The Office of Tissue Advancement Therapies, a branch of the Center for Biologics Evaluation and Research of the FDA, has progressed toward the acceptance of Ampio Pharmaceuticals' Ampion for a viable treatment option for severe osteoarthritis of the knee. Read More »

Bristol-Myers and Pfizer to present on diverse topics at ACC

The companies will present real-world data analyses that showcase their commitment to understanding direct oral anticoagulants in clinical practice.

Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »

FDA to review type 2 diabetes drugs from Merck and Pfizer

The NDAs are for medicines containing ertugliflozin, an investigational SGLT2 inhibitor.

Merck, which is known as MSD outside the United States and Canada, and Pfizer Inc. recently announced the acceptance for review of three New Drug Applications by the U.S. Food and Drug Administration. Read More »

Amgen to release results of Repatha cardiovascular outcomes trial

The presentation will include two analyses that explore prescription rejection rates and access barriers for PCSK9 inhibitors.

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »

Goodlatte calls on legal profession to crack down on trial lawyer drug lawsuit ads

LocalLabs News Service | Mar 10, 2017

U.S. House Judiciary Chairman Bob Goodlatte (R-VA) has sent letters to the American Bar Association and every state bar association, urging the organizations to adopt requirements for warnings on trial lawyer advertisements that urge patients to discontinue the use of some medicines. Read More »

Epic to be implemented at CVS Specialty and Accordant

The Epic EHR system will be used by CVS Specialty.

CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »

Janssen lifts voluntary hold on FAAH Phase 2 study

Janssen had not been given any indication of negative results from their Phase 2 studies with the FAAH inhibitor.

Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies. Read More »

Keck student earns $1,000 scholarship from MD Labs

The $1,000 scholarship is offered each year for graduate students who are pursuing a career in pharmacy.

Kim Nguyen, La Puenta, Calif., was recently named the recipient of the MD Labs/Rxight Scholarship Supporting Excellence in Pharmacy Students. Read More »

Sandoz presents highlights from Phase 3 study of Humira biosimilar

In the study, 67 percent of patients saw a 75 percent improvement at Week 16 for the treatment of psoriasis.

Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »

Takeda, Cognition Kit to investigate depression diagnosis app

An Apple Watch app could assess cognitive function in patients with Major Depressive Disorder.

Takeda Pharmaceuticals U.S.A. Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd., is collaborating with Cognition Kit Ltd., a joint venture between Cambridge Cognition Holdings PLC and Ctrl Group Ltd., to pilot the use of an Apple Watch app that assesses cognitive function in patients with Major Depressive Disorder. Read More »

Arquette to head National Association of Specialty Pharmacy

Sheila Arquette has been involved in the specialty pharmacy industry for years.

The National Association of Specialty Pharmacy named Sheila Arquette its new executive director. Read More »

Janssen releases Phase 3 study findings for psoriasis treatment

The majority of patients treated with guselkumab achieved high levels of skin improvement.

Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »

California pharmacists cleared to prescribe contraceptives in some cases

Pharmacists will suggest that the women return for a follow-up visit.

California Pharmacists are now legally permitted to prescribe oral, transdermal and vaginal forms of hormonal contraceptives in certain situations. Read More »

Study links PPIs to kidney failure in 125,000 patients

The study found that 125,000 individuals who used PPIs suffered from kidney failure.

In a recent February 2017 study, by Kidney International, found that Proton Pump Inhibitors (PPIs), may cause adverse effects on the human kidney. Read More »

FDA approves ALK's application for dust mite allergy tablet

The medication is specially suited to address house dust mite-induced rhinitis.

The Food and Drug Administration has approved ALK's Biologics License Application for a sublingual immunotherapy tablet aimed at combating the negative effects caused by dust mite allergies. Read More »

FDA approves Noctivia for adults who deal with nocturnal polyuria

Noctivia nasal spray has gained FDA approval for adults who deal with nocturnal polyuria.

The U.S. Food and Drug Administration has approved Noctivia nasal spray for adults who deal with nocturnal polyuria, a condition that causes overproduction of urine during the night. Read More »

BioPharm shares pre-clinical data for BPX-01 topical gel

BPX-01 is a topical gel that can fight acne in a target area without any side effects.

BioPharm X Corp., a specialty pharmaceutical company focused on the dermatology market, recently shared early clinical and pre-clinical data for BPX-01 topical gel at the 2017 American Academy of Dermatology (AAD) Annual Meeting. Read More »

Immune Pharmaceuticals extends enrollment for BP drug study

Bullous Pemphigoid is a rare autoimmune disease that causes blistering.

Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »

Incyte, Penn's Abramson Cancer Center partner on study

Penn’s investigators will use knowledge and expertise in preclinical biology to research Incyte’s novel therapeutics.

Incyte Corp. will conduct a multi-year research project in conjunction with the Abramson Cancer Center at the University of Pennsylvania aimed at advancing the understanding of cancer biology. Read More »

Teva Pharmaceuticals adds Pristiq 1 generic to portfolio